SGLT2 inhibitors, when used alone or in combination with metformin, are also associated with reduced risk of hypoglycemia by increasing plasma glucagon concentrations and decreasing plasma insulin concentrations21,22. The gene discussed is GCG; the disease is Hypoglycemia.